A puzzling microbiological and clinical discrepancy in the management of acute, severe skin-soft tissue and joint staphylococcal infection. In vitro antimicrobial susceptibility to glycopeptides, versus in vivo clinical efficacy of linezolid alone

Infezioni in Medicina

Volumn 14, Issue 3, 2006, Pages 157-164

  Manfredi, Roberto ^a   Sabbatani, Sergio ^a   Nanetti, Anna ^a   Chiodo, Francesco ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Glycopeptides; Joint infection; Linezolid; Rifampicin; Staphylococci

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; GLYCOPEPTIDE; IMIPENEM; LINEZOLID; RIFAMPICIN; TEICOPLANIN; VANCOMYCIN;

ADULT; ANAMNESIS; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATION; BLOOD CULTURE; CASE REPORT; DEBRIDEMENT; DISEASE SEVERITY; DRUG EFFICACY; HOSPITAL ADMISSION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFECTIOUS ARTHRITIS; KNEE ARTHRITIS; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; SOFT TISSUE INFECTION; STAPHYLOCOCCUS INFECTION;

ACETAMIDES; ACUTE DISEASE; ANTI-INFECTIVE AGENTS; GLYCOPEPTIDES; HUMANS; JOINT DISEASES; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; OXAZOLIDINONES; SEVERITY OF ILLNESS INDEX; SOFT TISSUE INFECTIONS; STAPHYLOCOCCAL INFECTIONS;

EID: 33846846016     PISSN: 11249390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Mutnick A.H., Biedenback D.J., Turnidge J.D., Jones R.N. Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998-2000. Diagn. Microbiol. Infect. Dis. 43, 66-73, 2002.
2. Meka V.G., Gold H.S. Antimicrobial resistance to linezolid. Clin. Infect. Dis. 39, 1010-1015, 2004.
3. Manfredi R., Nanetti A., Morelli S., Valentini R., Calza L., Chiodo F. Sensitivity of methicillin-resistant Staphylococcus aureus (MRSA) to antimicrobial agents other than beta-lactams: profile and trend, 1998-2003. Isr. Med. Assoc. J. 6, 191-192, 2004.
4. Perry C.M., Jarvis B. Linezolid. A review of its use in the management of serious Gram-positive infections. Drugs 61, 525-551, 2001.
5. Manfredi R. A re-emerging class of antimicrobial agents: streptogramins (quinupristin/dalfopristin) in the management of multiresistant gram-positive nosocomial cocci in hospital setting. Mini Rev. Clin. Chem. 2005 (in press).
6. Wilcox M.H. Efficacy of linezolid versus comparator therapies in Gram-positive infections. J. Antimicrob. Chemother. 51 (Suppl. 2), ii27-ii35, 2003.
7. Wunderink R.G., Cammarata, S.K., Oliphant, T.H., Kollef, M.H. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin. Ther. 25, 980-992, 2003.
8. Stevens D.L., Smith L.G., Bruss J.B., McConnell-Martin M.A., Duvall D.E., Todd W.M., et al. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob. Agents Chemother. 44, 3408-3413, 2000.
9. Vinken A.G., Li J.Z., Balan D.A., Rittenhouse B.E., Willke R.J., Goodman C. Comparison of linezolid with oxacillin or vancomycin in the empiric treatment of cellulitis in US Hospitals. Am. J. Ther. 10, 264-274, 2003.
10. Lipsky B.A., Itani K., Norden C. Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate. Clin. Infect. Dis. 38, 17-24, 2004.
11. Kaplan S.L., Deville J.G., Yogev R., Morfin M.R., Wu E., Adler S., et al. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatr. Infect. Dis. J. 22, 677-686, 2003.
12. Ravindran V., John J., Kaye G.C., Meigh R.E. Successful use of oral linezolid as a single active agent in endocarditis unresponsive to conventional antibiotic therapy. J. Infect. 47, 164-166, 2003.
13. Sabbatani S., Manfredi R., Frank G., Chiodo F. Capnocytophaga brain abscess in an immunocompetent host: problems in antimicrobial chemotherapy and literature review. J. Chemother. 16, 497-501, 2004.
14. Melzer M., Goldsmith D., Gransden W. Successful treatment of vertebral osteomyelitis with linezolid in a patient receiving hemodyalisis and with persistent methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus bacteremias. Clin. Infect. Dis. 31, 208-209, 2000.
15. Birmingham M.C., Rayner C.R., Meagher A.K., Flavin S.M., Batts D.H., Schentag J.J. Linezolid for the treatment of multidrug-resistant, Gram-positive infections: experience from a compassionate-use program. Clin. Infect. Dis. 36, 159-168, 2003.
16. Howden B.P., Ward P.B., Charles P.G.P. et al. Treatment outcomes for serious infectious caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin. Infect. Dis. 38, 521-528, 2004.
17. Rao N., Ziran B.H., Hall R.A., Santa E.R. Successful treatment of chronic bone and joint infections with oral linezolid. Clin. Orthop. 427, 67-71, 2004.
18. Razonable R.R., Osmon D.R., Steckelberg J.M. Linezolid therapy for orthopedic infections. Mayo Clin. Proc. 79, 1137-1144, 2004.
19. Harwood P.J., Giannoudis P.V. The safety and efficacy of linezolid in orthopaedic practice for the treatment of infection due to antibiotic-resistant organisms. Expert Opin. Drug Saf. 3, 405-414, 2004.
20. Wilson A.P. Clinical pharmacokinetics of teicoplanin. Clin. Pharmacokinet. 39, 167-183, 2000.
21. Deville J.G., Adler S., Azimi P.H., Jantausch B.A., Morfin M.R., Beltran S, et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates. Pediatr. Infect. Dis. J. 22 (Suppl. 9), S158-A163, 2003.
22. Nathwani D. Economic impact and formulary positioning of linezolid: a new anti-Gram positive antimicrobial. J. Hosp. Infect. 49 (Suppl. A), S33-S41, 2001.
23. Nathwani D., Li J.Z., Balan D.A., Willke R.J., Rittenhouse B.E., Mozaffari E., et al. An economic evaluation of a European cohort from a multinational trial of linezolid versus teicoplanin in serious Gram-positive bacterial infections: the importance of treatment setting in evaluating treatment effects. Int. J. Antimicrob. Agents. 23, 315-324, 2004.
24. Nathwani D, Barlow G.D., Ajdukiewicz K., Gray K., Morrison J., Clift B., et al. Cost-minimization analysis and audit if antibiotic management of bone and joint infections with ambulatory teicoplanin, in-patient care or outpatient oral linezolid therapy. J. Antimicrob. Chemother. 51, 391-396, 2003.
25. National Centres for Clinical and Laboratory Standards (NCCLS). Performance standards for antimicrobial susceptibility testing, 2004; 24 (1), 40-45, 104-109, 2004.
26. Rayner C.R., Baddour L.M., Birmingham M.C., Norden C., Meagher A.K., Shentag J.J. Linezolid in the treatment of osteomyelitis: results of a compassionate use experience. Infection 32, 8-14, 2004.
27. Moise, P.A., Forrest, A., Birmingham, M.C., Schentag J.J. The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, of who have failed to respond to, vancomycin. J. Antimicrob. Chemother. 50, 1017-1026, 2002.
28. Cepeda J.A., Whitehouse T, Cooper B, et al. Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study. J. Antimicrob. Chemother. 53, 345-355, 2004.
29. Rana B., Butcher I., Grigoris P., Murnaghan C., Seaton R.A., Tobin C.M. Linezolid penetration into osteo-articular tissues. J. Antimicrob. Chemother. 50, 747-750, 2002.
30. Kutscha-Lisssberg F., Hebler U., Muhr G., Koller M. Linezolid penetration into bone and joint tissues infected with methicillin-resistant staphylococci. Antimicrob. Agents Chemother. 47, 3964-3966, 2003.